1.82
1.40%
0.03
アフターアワーズ:
1.82
前日終値:
$1.79
開ける:
$1.81
24時間の取引高:
1.43M
Relative Volume:
0.80
時価総額:
$392.73M
収益:
$194.75M
当期純損益:
$-51.26M
株価収益率:
-3.50
EPS:
-0.52
ネットキャッシュフロー:
$-23.38M
1週間 パフォーマンス:
-2.42%
1か月 パフォーマンス:
+32.48%
6か月 パフォーマンス:
+60.62%
1年 パフォーマンス:
+84.26%
Akebia Therapeutics Inc Stock (AKBA) Company Profile
名前
Akebia Therapeutics Inc
セクター
電話
617-871-2098
住所
245 FIRST STREET, CAMBRIDGE, MA
AKBA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
AKBA | 1.82 | 392.73M | 194.75M | -51.26M | -23.38M | -0.52 |
ZTS | 176.72 | 79.33B | 9.15B | 2.43B | 2.31B | 4.92 |
HLN | 9.55 | 43.04B | 14.26B | 1.55B | 0 | 0.3327 |
TAK | 13.32 | 42.13B | 30.27B | 1.93B | 3.45B | 0.444 |
TEVA | 17.07 | 19.29B | 16.77B | -959.00M | 1.37B | -2.00 |
VTRS | 13.25 | 15.77B | 15.24B | -646.50M | 1.88B | 1.53 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2022-03-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2022-03-31 | ダウングレード | Mizuho | Buy → Neutral |
2022-03-31 | ダウングレード | Needham | Buy → Hold |
2022-03-31 | ダウングレード | Piper Sandler | Overweight → Neutral |
2021-03-08 | 開始されました | Cantor Fitzgerald | Overweight |
2021-01-29 | ダウングレード | JP Morgan | Neutral → Underweight |
2019-11-14 | 繰り返されました | Needham | Buy |
2019-08-06 | 繰り返されました | H.C. Wainwright | Buy |
2019-07-11 | 繰り返されました | H.C. Wainwright | Buy |
2019-05-02 | 開始されました | JP Morgan | Overweight |
2019-03-20 | 開始されました | Citigroup | Neutral |
2018-09-07 | 再開されました | Morgan Stanley | Equal-Weight |
2018-08-10 | 繰り返されました | Needham | Buy |
2018-06-06 | 繰り返されました | H.C. Wainwright | Buy |
2017-12-19 | 開始されました | Piper Jaffray | Overweight |
2017-12-07 | 開始されました | BTIG Research | Buy |
2017-09-15 | 開始されました | RBC Capital Mkts | Sector Perform |
2017-07-10 | 繰り返されました | H.C. Wainwright | Buy |
2017-04-27 | 繰り返されました | H.C. Wainwright | Buy |
2017-04-27 | 繰り返されました | Needham | Buy |
2016-12-27 | 繰り返されました | H.C. Wainwright | Buy |
2016-12-20 | 繰り返されました | JMP Securities | Mkt Outperform |
2016-11-15 | 開始されました | Aegis Capital | Buy |
2016-09-29 | 開始されました | Brean Capital | Buy |
2016-03-16 | 繰り返されました | Needham | Buy |
2016-01-21 | 開始されました | Credit Suisse | Neutral |
すべてを表示
Akebia Therapeutics Inc (AKBA) 最新ニュース
Q3 2024 Earnings: Hold Akebia Therapeutics (NASDAQ:AKBA) - Seeking Alpha
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease - Yahoo Finance UK
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com - Defense World
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - StockTitan
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2024 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50 - Yahoo Finance
Earnings call: Akebia reports Q3 results, gears up for Vafseo launch - Investing.com Australia
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41% - Simply Wall St
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... - Yahoo Finance
Akebia Therapeutics: Q3 Earnings Snapshot - CT Insider
Akebia Therapeutics Prepares for Vafseo Launch - TipRanks
Akebia Therapeutics Inc. (AKBA) Quarterly 10-Q Report - Quartzy
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - citybiz
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
SEC Form 10-Q filed by Akebia Therapeutics Inc. - Quantisnow
Here's Why You Should Consider Buying Akebia (AKBA) Stock - MSN
Akebia Therapeutics to present at upcoming investor conferences - MSN
Akebia Therapeutics (AKBA) Scheduled to Post Earnings on Thursday - MarketBeat
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Lelezard
Akebia Therapeutics Signs Commercial Supply Contract with Leadin - GuruFocus.com
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights - citybiz
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Down 6.0% in October - Defense World
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Reaffirmed by HC Wainwright - Defense World
Akebia stock climbs 8% on dialysis provider supply agreement - MSN
High Growth Tech Stocks to Watch in October 2024 - Simply Wall St
Akebia Therapeutics (NASDAQ:AKBA) shareholder returns have been respectable, earning 91% in 1 year - Simply Wall St
Akebia Therapeutics secures dialysis drug contract By Investing.com - Investing.com Australia
Akebia Therapeutics secures dialysis drug contract - Investing.com
Akebia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - Yahoo Finance
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionAKBA - AsiaOne
Akebia Therapeutics extends supply agreement with STA Pharmaceutical - Investing.com
Akebia Therapeutics extends supply agreement with STA Pharmaceutical By Investing.com - Investing.com UK
Akebia Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 - StockTitan
A new trading data show Akebia Therapeutics Inc. (AKBA) is showing positive returns. - SETE News
Akebia Therapeutics Inc.’s latest rating changes from various analysts - Knox Daily
Akebia shares maintain Buy rating on CMS Vafseo payment decision By Investing.com - Investing.com Canada
Marshall Wace LLP Lowers Stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
Akebia shares maintain Buy rating on CMS Vafseo payment decision - Investing.com India
Akebia Therapeutics Inc (AKBA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):